EAGLE PHARMACEUTICALS, INC.
EGRXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for EGRX. That does not mean none is planned.
Get an email about EGRX's next catalysts
Track EAGLE PHARMACEUTICALS (EGRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Ryanodex and Standard of Care
Exertional Heat Stroke
Mesalamine
Mild to Moderate Ulcerative Colitis
CAL02
Pneumonia, Bacterial
Dantrolene sodium for injectable suspension
Heat Stroke
SeeMore(TM)
Myocardial Infarction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ryanodex and Standard of Care | Phase 3 | Exertional Heat Stroke | - | - |
Mesalamine | Phase 3 | Mild to Moderate Ulcerative Colitis | - | - |
CAL02 | Phase 2 | Pneumonia, Bacterial | - | - |
Dantrolene sodium for injectable suspension | Phase 2 | Heat Stroke | - | - |
SeeMore(TM) | Phase 2 | Myocardial Infarction | - | - |
Frequently asked questions
What is in EAGLE PHARMACEUTICALS, INC.'s drug pipeline?β
CatalystAlert tracks 5 drug candidates in EAGLE PHARMACEUTICALS, INC.'s (EGRX) pipeline across Phase 3, Phase 2. Its lead program is Mesalamine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EAGLE PHARMACEUTICALS, INC.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for EAGLE PHARMACEUTICALS, INC. (EGRX) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track EGRX biotech catalysts?β
Add EGRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EAGLE PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
